Zulkiewicz, Brittany A
Chen, Jarvis T.
Hanby, Elaine P.
Ramanadhan, Shoba
Obedin-Maliver, Juno
Lunn, Mitchell R.
Scout, N. F. N.
Gordon, Bob
Applegate, Julia
Machado, Ana
Viswanath, Kasisomayajula
Potter, Jennifer
Liu, Sixiao
Tan, Andy S. L.
Funding for this research was provided by:
National Cancer Institute (R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670, R01CA237670)
Article History
Received: 6 March 2024
Accepted: 29 October 2024
First Online: 15 November 2024
Declarations
:
: MRL has received consulting fees from Hims, Inc. (2019-present), Folx Health, Inc. (2019-2021), and Otsuka Pharmaceutical Development and Commercialization, Inc. (2023). JOM has consulted for Sage Therapeutics (2017), Ibis Reproductive Health (2017-2018, 2020-present), Hims, Incorporated (2019-present), and Folx, Incorporated (2019-present). None of these engagements influenced or are pertinent to the work described in this manuscript. All other authors do not have any competing interest to declare.